China SXT Pharmaceuticals Stock Scheduled to Reverse Split on Monday, August 10th (NASDAQ:SXTC)

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) shares are going to reverse split on the morning of Monday, August 10th. The 1-80 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 9th.

China SXT Pharmaceuticals Trading Down 19.6%

Shares of NASDAQ:SXTC traded down $0.01 on Thursday, hitting $0.05. The company’s stock had a trading volume of 46,705,100 shares, compared to its average volume of 112,669,208. The company has a 50-day simple moving average of $1.76 and a 200 day simple moving average of $2.66. China SXT Pharmaceuticals has a 1 year low of $0.05 and a 1 year high of $1,046.98. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94.

China SXT Pharmaceuticals (NASDAQ:SXTC) last issued its quarterly earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.26 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC bought a new position in shares of China SXT Pharmaceuticals during the 3rd quarter valued at about $78,000. XTX Topco Ltd bought a new stake in China SXT Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, Virtu Financial LLC boosted its stake in China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after buying an additional 15,013 shares in the last quarter. 5.02% of the stock is currently owned by hedge funds and other institutional investors.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.